Role of Immunotherapy in Bacillus Calmette-Guérin-unresponsive Non-muscle Invasive Bladder Cancer

Overview

Journal Urol Oncol

Publisher Elsevier

Date 2018 Feb 13

PMID 29429897

Citations 10

Authors

Neelam Mukherjee

Robert S Svatek

Ahmed M Mansour

Affiliations

Soon will be listed here.

Abstract

Intravesical instillation of live attenuated bacillus Calmette-Guérin (BCG) is the gold standard for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). BCG-failures include a heterogenous population of patients who share a designation of disease recurrence or progression following BCG and include patients with complete unresponsiveness to BCG, patients who respond initially but develop relapse and, in some cases, patients who are intolerant to BCG due to side effects. Given the efficacy and relatively rapid approval of several monoclonal antibodies against PD-L1 or PD-1 for advanced and metastatic bladder cancer, the role of these checkpoint inhibitors in BCG-relapsing disease at various disease stages is under consideration. Data supporting a role for immune checkpoint inhibitors is largely theoretical with limited supportive data from animal models and from clinical evidence of increased PD-L1 expression in BCG-unresponsive tumors. Current trials in BCG-unresponsive disease are underway and expected to provide insight regarding these concepts.

Citing Articles

Proteomic analysis of the urothelial cancer landscape.

Dressler F, Diedrichs F, Sabtan D, Hinrichs S, Krisp C, Gemoll T Nat Commun. 2024; 15(1):4513.

PMID: 38802361 PMC: 11130393. DOI: 10.1038/s41467-024-48096-5.

Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.

Ramamurthy C, Wheeler K, Trecarten S, Hassouneh Z, Ji N, Lee Y J Cancer Immunol (Wilmington). 2024; 6(1):29-39.

PMID: 38784962 PMC: 11113005. DOI: 10.33696/cancerimmunol.6.081.

Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.

Noel O, Hassouneh Z, Svatek R, Mukherjee N Cancer Immunol Res. 2023; 12(2):149-160.

PMID: 38060011 PMC: 11492724. DOI: 10.1158/2326-6066.CIR-23-0414.

Acts as an Oncogene in Bladder Cancer.

Huang N, Peng L, Yang J, Li J, Zhang S, Sun M Cancers (Basel). 2023; 15(21).

PMID: 37958297 PMC: 10648174. DOI: 10.3390/cancers15215122.

Vaccination against Extracellular Vimentin for Treatment of Urothelial Cancer of the Bladder in Client-Owned Dogs.

Engbersen D, van Beijnum J, Roos A, van Beelen M, de Haan J, Grinwis G Cancers (Basel). 2023; 15(15).

PMID: 37568772 PMC: 10417384. DOI: 10.3390/cancers15153958.

References

Lamm D, Blumenstein B, Crissman J, Montie J, Gottesman J, Lowe B . Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163(4):1124-9. View

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

Inman B, Sebo T, Frigola X, Dong H, Bergstralh E, Frank I . PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007; 109(8):1499-505. DOI: 10.1002/cncr.22588. View

Mangsbo S, Ninalga C, Essand M, Loskog A, Totterman T . CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother. 2007; 31(1):34-42. DOI: 10.1097/CJI.0b013e3181587d29. View

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

Gulley J, Arlen P, Tsang K, Yokokawa J, Palena C, Poole D . Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008; 14(10):3060-9. PMC: 2673097. DOI: 10.1158/1078-0432.CCR-08-0126. View

Boorjian S, Sheinin Y, Crispen P, Farmer S, Lohse C, Kuntz S . T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008; 14(15):4800-8. DOI: 10.1158/1078-0432.CCR-08-0731. View

Martinez-Pineiro J, Jimenez Leon J, Fiter L, Mosteiro J, Navarro J, Garcia Matres M . Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol. 1990; 143(3):502-6. DOI: 10.1016/s0022-5347(17)40002-4. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

10.

Burke J, Lamm D, Meng M, Nemunaitis J, Stephenson J, Arseneau J . A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012; 188(6):2391-7. DOI: 10.1016/j.juro.2012.07.097. View

11.

Dinney C, Fisher M, Navai N, ODonnell M, Cutler D, Abraham A . Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013; 190(3):850-6. PMC: 3951790. DOI: 10.1016/j.juro.2013.03.030. View

12.

Shah J, Kamat A . Strategies for optimizing bacillus Calmette-Guérin. Urol Clin North Am. 2013; 40(2):211-8. DOI: 10.1016/j.ucl.2013.01.012. View

13.

Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn B, Comperat E . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64(4):639-53. DOI: 10.1016/j.eururo.2013.06.003. View

14.

Jarow J, Lerner S, Kluetz P, Liu K, Sridhara R, Bajorin D . Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2013; 83(2):262-4. DOI: 10.1016/j.urology.2013.10.030. View

15.

Maeyama J, Takatsuka H, Suzuki F, Kubota A, Horiguchi S, Komiya T . A palindromic CpG-containing phosphodiester oligodeoxynucleotide as a mucosal adjuvant stimulates plasmacytoid dendritic cell-mediated T(H)1 immunity. PLoS One. 2014; 9(2):e88846. PMC: 3933336. DOI: 10.1371/journal.pone.0088846. View

16.

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L . Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One. 2014; 9(6):e96705. PMC: 4045574. DOI: 10.1371/journal.pone.0096705. View

17.

Boussiotis V, Chatterjee P, Li L . Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J. 2014; 20(4):265-71. PMC: 4151049. DOI: 10.1097/PPO.0000000000000059. View

18.

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View

19.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

20.

La-Beck N, Jean G, Huynh C, Alzghari S, Lowe D . Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy. 2015; 35(10):963-76. DOI: 10.1002/phar.1643. View